WallStSmart

Kenvue Inc. (KVUE)vsArcadia Biosciences Inc (RKDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kenvue Inc. generates 311222% more annual revenue ($15.12B vs $4.86M). KVUE leads profitability with a 9.7% profit margin vs -48.1%. KVUE earns a higher WallStSmart Score of 58/100 (C).

KVUE

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 6.5Value: 4.7Quality: 4.5
Piotroski: 3/9Altman Z: 1.22

RKDA

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.3
Piotroski: 3/9Altman Z: -29.86
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KVUESignificantly Overvalued (-15.9%)

Margin of Safety

-15.9%

Fair Value

$16.00

Current Price

$17.53

$1.53 premium

UndervaluedFair: $16.00Overvalued
RKDAUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$4.01

Current Price

$1.05

$2.96 discount

UndervaluedFair: $4.01Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KVUE0 strengths · Avg: 0/10

No standout strengths identified

RKDA2 strengths · Avg: 9.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

EPS GrowthGrowth
28.5%8/10

Earnings expanding 28.5% YoY

Areas to Watch

KVUE3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.2%4/10

3.2% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

RKDA4 concerns · Avg: 2.5/10
Market CapQuality
$2.20M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-45.1%2/10

ROE of -45.1% — below average capital efficiency

Revenue GrowthGrowth
-25.9%2/10

Revenue declined 25.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : KVUE

PEG of 1.48 suggests the stock is reasonably priced for its growth.

Bull Case : RKDA

The strongest argument for RKDA centers on Price/Book, EPS Growth.

Bear Case : KVUE

The primary concerns for KVUE are Revenue Growth, Piotroski F-Score, Altman Z-Score.

Bear Case : RKDA

The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

KVUE profiles as a value stock while RKDA is a turnaround play — different risk/reward profiles.

RKDA carries more volatility with a beta of 0.72 — expect wider price swings.

KVUE is growing revenue faster at 3.2% — sustainability is the question.

KVUE generates stronger free cash flow (744M), providing more financial flexibility.

Bottom Line

KVUE scores higher overall (58/100 vs 37/100). RKDA offers better value entry with a 56.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kenvue Inc.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kenvue Inc. is a consumer health company globally.

Visit Website →

Arcadia Biosciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.

Visit Website →

Want to dig deeper into these stocks?